In early 1966, Zhuzhou Pharmaceutical Company began to prepare for the establishment of a Chinese patent medicine processing plant, producing Xiangqu, Liuyi Powder, Cough Loquat Dew and other products. In line with the important instructions of "focusing health work on rural areas", the Chinese patent medicine processing factory was renamed "Zhuzhou Liu·26 Pharmaceutical Factory".
In early 1975, the factory was renamed from "Zhuzhou Liu·26 Pharmaceutical Factory" to "Zhuzhou Traditional Chinese Medicine Pharmaceutical Factory".
In 1979, the factory developed a good gynecological medicine—Fynecological Qianjin Tablets and registered the trademark "Peony". The successful development of Gynecological Qianjin Tablets laid the foundation for the subsequent development of the factory and played a key role.
In 1981, due to the high cost of products and low product sales of the Zhuzhou Traditional Chinese Medicine Pharmaceutical Factory, the factory was in extremely difficult circumstances and was listed as a target for closure and transfer by the Zhuzhou Municipal People's Government. In the same year, the research on the disinfection and sterilization technology of Gynecology Qianjin Tablets was successful.
In 1983, "Gynecology Qianjin Tablets" was rated as a high-quality product in Hunan Province.
In April 1984, the superior authorities adjusted the factory leadership team: Zhu Feijin was appointed as the factory director and began to lead all employees to carry out arduous and fruitful entrepreneurship, so that the company could get out of difficulties and enter healthy development. track. In the same year, Peony brand "Naolejing" was rated as a quality product in Hunan Province.
In 1985, "Gynecology Qianjin Tablets" was rated as a high-quality product by the State Administration of Medicine.
In 1987, it was renamed Zhuzhou Traditional Chinese Medicine Factory. In 1991, Gynecological Qianjin Film won the National Silver Award for Excellence.
In June 1993, with the approval of the Hunan Provincial Economic and Technological Reform Commission, the Traditional Chinese Medicine Factory took the lead in the province's pharmaceutical industry to reorganize its enterprise into a joint-stock company. Restructuring is an important milestone in the history of enterprise development. It provides opportunities and vitality for the enterprise's subsequent rapid growth. Through the restructuring, on the one hand, more than 3 million yuan of funds were raised for technological transformation and replenishing working capital. On the other hand, the factory seized the opportunity of the restructuring, focused on transforming the operating mechanism, and initially established a system where employees can enter and exit, A new operating mechanism that allows leaders to be promoted and demoted, and wages to be raised or lowered.
In 1993, after six years of hard work, the company and Hunan College of Traditional Chinese Medicine jointly developed the national new drug Gubentongxue Granules, which was approved for production. This was the first time since the country implemented new drug evaluation methods in 1985 ( By 1993), it was the first national-level new drug in Zhuzhou City (the second in the province).
Beginning in the second half of 1993, the company invested 1.7 million yuan to comprehensively renovate tablet, wine and granule production lines in the original factory in accordance with GMP requirements.
In July 1994, the company completed the merger of Zhuzhou Zipper Factory. In the same year, Gynecology Qianjin Tablet was selected as a national essential medicine.
In 1995, a trading branch (the predecessor of Qianjin Medicine) was established at the original site of the City Zipper Factory. The main task of the trading branch at the beginning was to assist the marketing department of the head office in recovering the company's old accounts. In the same year, the "Qianjin" brand trademark obtained the registered trademark certificate from the State Administration for Industry and Commerce.
In 1996, "Gynecology Qianjin Tablets" was recognized as the Hunan Famous Brand Product in 1995. Since the first half of the year, the main product, Gynecological Qianjin Tablets, has always been in short supply. In order to solve the shortage of Gynecological Qianjin Tablets, the first phase of the technical transformation project of Gynecological Qianjin Tablets started in 1996. It passed the acceptance inspection at the end of 1997 and was officially put into production in early 1998. The production capacity doubled. After much research, it was put into production that year, reached production volume that year, and achieved results that year. The profit increased by nearly 10 million yuan within one year of production.
In 1996, upon review and approval by the shareholders' meeting, the company increased capital and expanded its shares by allocating 1.5 shares to all shareholders for every 10 shares and allocating 7.5 shares, and the total share capital was expanded to 19 million shares. In 1997, the company applied to the Zhuzhou Municipal Securities Commission for "over-the-counter trading of individual stocks", and on June 29, it was listed for over-the-counter trading in the Hetai Trading Hall of Hunan Securities Zhuzhou Company. In 1998, in accordance with the requirements of relevant national ministries and commissions, over-the-counter trading of individual stocks was stopped.
In 1998, major measures were taken in foreign investment: it invested 8.16 million yuan to acquire the Zhuzhou Xiangjiang Pharmaceutical Factory, and registered and established a medicinal materials branch in Longxi, Gansu.
In 1998, the Zhuzhou Municipal People's Government listed the company as one of the first pilot units in Zhuzhou City to adjust its property rights structure (operators holding large shares), and transferred 2.357 million state shares to the company's operating group and management backbone, forming a A new corporate property rights structure pattern in which employee shares hold a controlling position, operating group shares hold a controlling position, and operators hold a dominant shareholding has established a more rigid mechanism of corporate ownership and ownership responsibilities, and incentives and constraints. .
In 1999, the company began to work on GMP compliance acceptance. In December, it successfully passed the GMP compliance acceptance organized by the Provincial Food and Drug Administration and became the first batch of GMP certified enterprises in Hunan Province. In 2000, the company began the research and development of Gynecology Qianjin Capsules, a national Class IV new drug of traditional Chinese medicine, and obtained the new drug certificate in 2002. In the same year, the warranty renewal (seven years) of Gynecology Qianjin Tablets was successful, and the first health food series - Hongyan Chaorun Capsules and Good Night Capsules were approved, which laid a solid foundation for the company's second venture.
In 2001, Qianjin Pharmaceutical restructured Zhuzhou Cinema and established Zhuzhou Qianjin Cinema Co., Ltd., which was renamed Zhuzhou Qianjin Cultural Plaza Co., Ltd.
In 2002, the company's four dosage forms, including capsules, granules, syrups and wine, passed GMP certification. So far, the company has passed GMP certification as a whole.
In 2002, the company seized the opportunity and carried out the reform of "replacing state-owned capital and changing the identity of employees" in accordance with the spirit of relevant documents issued by the municipal party committee and municipal government. 358 employees signed the "Agreement on Economic Compensation for Termination of Labor Relations in Restructured Enterprises" with the company. From then on, company employees no longer have the status distinction of "state cadres", "citizen employees" and "collective employees". After changing the status, after passing the assessment, the labor contract and employment contract will be re-signed. Those who fail the assessment will no longer sign a labor contract. The intensity of this reform and the impact it has had on employees' ideological concepts is unprecedented in the company.
In the same year, the Gynecology Qianjin Capsule modernization project was listed as an important modernization project supported by the state. "Gynecology Qianjin Tablet" obtained the Phase II protection of the "National Protected Variety of Traditional Chinese Medicine";
In early 2001, the company made the decision to apply for listing and cooperated with Guotong Securities, Kyoto Accounting Firm and Qiyuan Law Firm and other intermediaries signed a guidance agreement for stock listing, and officially entered the pre-listing guidance period. In 2002, it passed the listing guidance and acceptance organized by the Saudi Arabian Office of the Chairman of the China Securities Regulatory Commission, and completed six projects including the "Gynecology Qianjin Capsule High-tech Industrialization Demonstration Project" Establishment of listed projects and demonstration by authoritative institutions. In the second half of 2002, the listing materials were submitted to the State Securities Regulatory Commission. On January 27, 2003, the stock listing was reviewed and approved by the State Securities Regulatory Commission.
On March 12, 2004, 18 million A shares of Qianjin Pharmaceutical were listed for trading on the Shanghai Stock Exchange (stock code 600479). The stock listing is another important milestone in the company's development history.
On December 26, 2005, Qianjin Pharmaceutical completed the share-trading reform. In the same year, the "Qianjin" trademark was recognized as a well-known trademark in China.
On March 30, 2006, Qianjin Pharmaceutical’s flagship product “Gynecology Qianjin Tablets” was jointly designated as a national secret technology by the Ministry of Science and Technology and the State Administration of Secrecy. Being rated as a national secret technology is a great affirmation of the company's products. Qianjin Pharmaceutical will use this as a new starting point to create greater glories and achieve new leaps.
In 2009, Gynecological Qianjin Tablets (capsules) were selected into the National Essential Drugs List; in the same year, Buxue Yimu Granules (pills) were selected into the National New Medical Insurance List.